Stalhammar J, Stern L, Linder R, Sherman S, Parikh RC, Ariely R, Wikstrom G. Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. J Med Econ. 2012 May;15(5):938-46.
Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012 Jan 1;15(1):166-74.
Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ. 2012;15(2):219-24. doi: 10.3111/13696998.2011.638954
Rebordosa C, Kogevinas M, Guerra S, Castro-Giner F, Jarvis D, Cazzoletti L. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. Eur Respir J. 2011 Nov;38(5):1029-35.
Twiss J, McKenna SP, Crawford SR, Tammaru M, Oprandi NC. Adapting the Asthma Life Impact Scale (ALIS) for use in Southern European (Italian) and Eastern European (Russian) cultures. J Med Econ. 2011;14(6):729-38. doi: 10.3111/13696998.2011.615356
Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ. 2011 Jan 1;14(1):99-107.
Henneberger PK, Mirabelli MC, Kogevinas M, Anto JM, Plana E, Dahlman-Hoglund A. The occupational contribution to severe exacerbation of asthma. Eur Respir J. 2010 Oct;36(4):743-50.
Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ. 2010 Sep 1;13(3):403-17.
Olivieri M, Mirabelli MC, Plana E, Radon K, Anto JM, Bakke P. Healthy hire effect, job selection and inhalation exposure among young adults with asthma. Eur Respir J. 2010 Sep;36(3):517-23.
Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ. 2010;13(3):492-9. doi: 10.3111/13696998.2010.505863
Jacquemin B, Sunyer J, Forsberg B, Aguilera I, Buoso L, Briggs D, de Marco R, Garcia-Esteban R, Henrich J, Jarvis D, Maldonado JA, Payo F, Rage E, Vienneau D, Kunzli N. Association between modelled traffic-related air pollution and asthma score in the ECRHS. Eur Respir J. 2009 Oct;34(4):834-42. doi: 10.1183/09031936.00138208
Blanc PD, Menezes AM, Plana E, Mannino DM, Hallal PC, Toren K. Occupational exposures and COPD: an ecological analysis of international data. Eur Respir J. 2009 Feb;33(2):298-304.
Mauskopf JA, Boye KS, Schmitt C, McCollam P, Birt J, Juniper MD, Bakhai A. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. J Med Econ. 2009 Jan 1;12(2):141-53.
Sunyer J, Pistelli R, Plana E, Andreani M, Baldari F, Kolz M. Systemic inflammation, genetic susceptibility and lung function. Eur Respir J. 2008 Jul;32(1):92-7.
Ellison-Loschmann L, Sunyer J, Plana E, Pearce N, Zock JP, Jarvis D. Socioeconomic status, asthma and chronic bronchitis in a large community-based study. Eur Respir J. 2007 May;29(5):897-905.
Brodersen J, Meads DM, Kreiner S, Thorsen H, Doward LC, McKenna SP. Methodological aspects of differential item functioning in the Rasch model. J Med Econ. 2007;10:309-22.
Alexeyeva I, Mauskopf J, Earnshaw SR, Stauffer VL, Gibson JP, Ascher-Svanum H. Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling. J Med Econ. 2001 Jan 1;4:179-92.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.